Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics (NASDAQ: TNYA) has granted stock options to two new non-executive employees as employment inducements. The options allow purchase of 12,000 total shares at $1.97 per share, matching the November 15, 2024 closing price. These ten-year options vest over four years, with 25% vesting after one year and the remainder vesting monthly at 1/48th of the original shares. The grants were made under the company's 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Rule 5635(c)(4).
Tenaya Therapeutics (NASDAQ: TNYA) ha concesso opzioni su azioni a due nuovi dipendenti non esecutivi come incentivo all'assunzione. Le opzioni consentono l'acquisto di un totale di 12.000 azioni a 1,97 dollari ciascuna, corrispondente al prezzo di chiusura del 15 novembre 2024. Queste opzioni decennali maturano nell'arco di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente in base a 1/48 delle azioni originali. Le concessioni sono state effettuate nell'ambito del Piano di Incentivazione Equity 2024 della società, secondo la Regola NASDAQ 5635(c)(4).
Tenaya Therapeutics (NASDAQ: TNYA) ha otorgado opciones sobre acciones a dos nuevos empleados no ejecutivos como incentivo de empleo. Las opciones permiten la compra de un total de 12,000 acciones a 1.97 dólares por acción, coincidiendo con el precio de cierre del 15 de noviembre de 2024. Estas opciones de diez años se adquieren en un periodo de cuatro años, con un 25% ganando derechos después de un año y el resto adquiriéndose mensualmente a razón de 1/48 de las acciones originales. Las concesiones se realizaron bajo el Plan de Incentivo de Capital por Inducción 2024 de la empresa, de acuerdo con la Regla NASDAQ 5635(c)(4).
테나야 테라퓨틱스 (NASDAQ: TNYA)는 새로운 비임원 직원 두 명에게 고용 유인을 위해 주식 옵션을 부여했습니다. 이 옵션은 총 12,000주를 주당 1.97달러에 구매할 수 있는 권리를 부여하며, 2024년 11월 15일의 종가에 해당합니다. 이 10년 만기 옵션은 4년 동안 분할해 소유권이 부여되며, 1년 후 25%가 부여되고 나머지는 원래 주식의 1/48씩 매달 부여됩니다. 이러한 부여는 NASDAQ 규정 5635(c)(4)에 따라 회사의 2024 유인 자본 인센티브 계획에 따라 이루어졌습니다.
Tenaya Therapeutics (NASDAQ: TNYA) a accordé des options d'achat d'actions à deux nouveaux employés non-exécutifs en tant qu'incitatif à l'embauche. Les options permettent l'achat d'un total de 12 000 actions au prix de 1,97 $ par action, correspondant au prix de clôture du 15 novembre 2024. Ces options de dix ans acquièrent des droits sur une période de quatre ans, avec 25 % des options acquérant des droits après un an et le reste acquérant des droits mensuellement à raison de 1/48 des actions d'origine. Les concessions ont été faites dans le cadre du Plan d'incitation à l'équité 2024 de la société, conformément à la règle NASDAQ 5635(c)(4).
Tenaya Therapeutics (NASDAQ: TNYA) hat zwei neuen nicht-executiven Mitarbeitern als Anreiz für die Anstellung Aktienoptionen gewährt. Die Optionen ermöglichen den Kauf von insgesamt 12.000 Aktien zu je 1,97 Dollar, was dem Schlusskurs vom 15. November 2024 entspricht. Diese zehnjährigen Optionen werden über vier Jahre verteilt und 25% werden nach einem Jahr fällig, der Rest monatlich mit 1/48 der ursprünglichen Anzahl an Aktien. Die Gewährung erfolgte im Rahmen des Aktienoptionsplans 2024 der Gesellschaft gemäß NASDAQ-Regel 5635(c)(4).
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement material to each new employee’s acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.
FAQ
How many shares were included in Tenaya Therapeutics (TNYA) November 2024 inducement grants?
What is the exercise price for TNYA's November 2024 inducement stock options?
What is the vesting schedule for TNYA's November 2024 inducement grants?
